Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Parkinson’s Foundation Designates NewYork-Presbyterian/Columbia, Rush University Medical Centers as Parkinson’s Care ‘Centers of Excellence’

As foundation continues to invest in programs to improve the lives of Parkinson’s patients, designation of new Centers of Excellence further expand expert care network
 

MIAMI & NEW YORK CITY — February 7, 2017—The Parkinson’s Foundation today announced the addition of two new Centers of Excellence to its global network: NewYork-Presbyterian/Columbia University Medical Center in New York City and Rush University Medical Center in Chicago.

The Center of Excellence network is a proving ground for new therapies and care models through grant programs and targeted initiatives such as the Parkinson’s Outcomes Project, the largest clinical study of Parkinson’s disease. This sought-after designation, based on clinical and research excellence, has achieved worldwide recognition.

“At Parkinson’s Foundation, we are proud that our longtime investment in NewYork-Presbyterian/Columbia and Rush has played a pivotal role in all significant Parkinson’s research advances,” said John L. Lehr, chief executive officer of Parkinson’s Foundation. “This newest designation recognizes that both institutions are successfully translating those research advancements into improvements in patient care – exactly what our community so urgently needs.”

Parkinson’s Foundation designates Centers of Excellence following a rigorous application and peer-review process. Currently, there is a worldwide network of 42 leading academic medical centers that leverage the interplay between cutting-edge research and exemplary patient-focused, multidisciplinary care. This network serves more than 100,000 individuals diagnosed with Parkinson’s disease. To participate in the competitive designation process, centers must first meet strict criteria for research, comprehensive care, patient outreach services and professional education. The network is widely credited with developing and promoting the modern Parkinson’s team model of care and ensuring that patients receive the highest standards of care.

With longstanding recognition as Research Centers by the Parkinson’s Foundation, NewYork-Presbyterian/Columbia and Rush each bring rich histories and unique strengths to the network. NewYork-Presbyterian/Columbia University Medical Center brings an illustrious history in cutting-edge translational research. Rush University offers tremendous innovation in clinical research.Both centers are renowned for their training of academic leaders worldwide.

“This designation is an enormous honor and recognition of the vital program that we have developed to integrate our three-part mission of research, education and patient care excellence,” said Christopher Goetz, M.D., professor of neurological sciences and pharmacology and director of the Parkinson’s Disease and Movement Disorder Program at Rush University Medical Center. “With this new designation, the faculty and staff will direct our efforts continually to enhance our services and work in partnership with our patients and families to meet these three missions.” 

Added Un Jung Kang, M.D., H. Houston Merritt Professor of Neurology and chief of the Division of Movement Disorders at NewYork-Presbyterian/Columbia University Medical Center: “We are delighted and honored to join our colleagues in the Parkinson’s Foundation Center of Excellence network. This designation is an important acknowledgement of our commitment to providing the best possible care and education, and engaging in community outreach about our expertise in translational research and patient care.”

The Parkinson’s Foundation brings all Centers of Excellence together annually to provide updates on care activities and research initiatives. This year’s Center of Excellence Leadership Conference is in Kansas City, Missouri, taking place May 4-6. The focus of this year’s meeting: Impacting Care for the Patients of Today and Tomorrow.” Every center must re-certify every five years to ensure that it maintains high standards of care. This process includes a review of achievements as well as a team-based peer evaluation, including an on-site assessment.

“Both NewYork-Presbyterian/Columbia and Rush have a long history of research and training that paved the way for the scientific and clinical networks of movement disorders centers,” said Peter Schmidt, Ph.D., chief mission officer and senior vice president of Research and Professional Programs at the National Parkinson Foundation, a division of the Parkinson’s Foundation. “We will change the course of Parkinson’s for tomorrow’s patients by improving care for everyone living with the disease today.”

To search for a Center of Excellence near you, visit www.parkinson.org/search.

About the Parkinson’s Foundation 
The Parkinson’s Foundation is working toward a world without Parkinson’s disease. Formed by the merger of National Parkinson Foundation and the Parkinson’s Disease Foundation in August 2016, the mission of the Parkinson’s Foundation is to invest in promising scientific research that will end Parkinson’s disease and improve the lives of people with Parkinson’s and their families through improved treatments, support and the best care. For more information, visit www.parkinsonsfoundation.org or call (800) 4PD-INFO (473-4636) or (800) 457-6676.

About Parkinson's Disease
Parkinson's disease is a progressive neurological disorder that affects nearly one million people in the US and over 10 million worldwide. Parkinson’s is the second most common neurodegenerative disease after Alzheimer's and is the 14th leading cause of death in the US. It is associated with a loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression A mood disorder whose symptoms can include a persistent sad or empty mood, feelings of hopelessness or pessimism, irritability and loss of interest or pleasure in previously enjoyable activities. and anxiety A feeling of nervousness, worried thoughts and physical distress.). Although promising research is being conducted, there is currently no cure for Parkinson's disease.

Monday, February 6, 2017
New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030
Tuesday, July 10, 2018

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Delegates From The Parkinson’s Community Converge On Capitol Hill To Advocate For Critical Research Funding
Monday, March 5, 2018

—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.